Skip to main content
. Author manuscript; available in PMC: 2015 Aug 7.
Published in final edited form as: Cell Signal. 2015 Mar 26;27(8):1666–1675. doi: 10.1016/j.cellsig.2015.03.014

Fig. 3.

Fig. 3

Phenotypic markers during combined GW5074, PP2 and RA treatment. R38+ and R38− HL-60 cells were treated for 48 h with RA, or RA combined with GW5074 (GW) and/or PP2 and analyzed by flow cytometry for (A) CD38 and CD11b expressions and (B) G1/G0 cell cycle arrest. PP2-treated R38+ and R38− HL-60 cells have been reported previously [25] but are recapitulated here for clear comparison. Error bars represent standard error. Asterisks for p-values of treatment group means compared to control indicate whether p < 0.0001 (****), p < 0.001 (***), p < 0.01 (**) or p < 0.05 (*). (A) GW5074-induced CD38 expression in higher than PP2 but GW5074-induced CD11b is reduced in R38+ and R38− cells. Combined PP2 + GW5074 with or without RA enhances markers even more in R38+ but actually decreases marker expression compared to GW5074 alone in R38−. (B) GW5074 does not appear to greatly increase the PP2-induced G1/G0 arrest in either RA-resistant HL-60 cell line.